

PCT

WORLD INTELLECTUAL PROPERTY  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER T.


WO 9605213A1

|   |  |  |  |
|---|--|--|--|
| (51) International Patent Classification <sup>6</sup> :<br><b>C07H 21/00, C07F 9/6561, 9/6558, A61K 31/70, C12Q 1/68</b>  |  | A1   | (11) International Publication Number: <b>WO 96/05213</b>        |
|   |  |  | (43) International Publication Date: 22 February 1996 (22.02.96) |
| (21) International Application Number: <b>PCT/EP95/03248</b>  |  | (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). |  |
| (22) International Filing Date: 14 August 1995 (14.08.95)   |  |  |  |
| (30) Priority Data:<br>94202342.5 17 August 1994 (17.08.94) NL<br>08/495,152 27 June 1995 (27.06.95) US   |  |  |  |
| (71) Applicant (for all designated States except US): STICHTING REGA VZW [BE/BE]; Minderbroederstraat 10, B-3000 Leuven (BE).   |  | <b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  |  |
| (72) Inventors; and   |  |  |  |
| (75) Inventors/Applicants (for US only): HERDEWIJN, Piet, André, Maurits [BE/BE]; Olivierstraat 21, B-3111 Rotselaar (BE). VAN AERSCHOT, Arthur, Albert, Edgard [BE/BE]; Heist-Goorstraat 29, B-2220 Heist o/d Berg (BE). |  |  |  |
| (74) Agent: VAN SOMEREN, Petronella, Francisca, Hendrika, Maria; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).   |  |  |  |

(54) Title: SEQUENCE-SPECIFIC BINDING OLIGOMERS FOR NUCLEIC ACIDS AND THEIR USE IN ANTISENSE STRATEGIES

## (57) Abstract

The invention relates to oligomers consisting completely or partially of 1,5-anhydrohexitol nucleoside analogues represented by general formula (I), wherein B is a heterocyclic ring which is derived from a pyrimidine or purine base, such as cytosine, 5-methylcytosine, uracil and thymine, or deaza derivatives thereof, or adenine, guanine, 2,6-diaminopurine, hypoxanthine and xanthine, or deaza derivatives thereof.



(I)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

**SEQUENCE-SPECIFIC BINDING OLIGOMERS FOR NUCLEIC ACIDS AND  
THEIR USE IN ANTISENSE STRATEGIES**

The present invention relates to oligomers having  
5 nucleic acid binding properties, which oligomers completely  
or partially consist of 1,5-anhydrohexitol nucleoside  
analogues as monomeric units. The invention further relates  
to the use of the oligomers in antisense techniques and to a  
method of preparing the oligomers.


10           Antisense techniques are based on the principle  
that the function of a coding sense strand of a DNA or RNA  
molecule may be blocked by a complementary antisense strand.  
Antisense techniques may be used for various applications,  
such as diagnosis, therapy, DNA modification and isolation  
15 etc.. In these techniques, besides the stability of the  
antisense strand itself, the stability of the duplex or  
triplex formed by the sense and antisense strands as well as  
the binding affinity of the antisense strand for the sense  
strand are of importance. Likewise, the sensitivity of the  
20 oligomer, the duplex or the triplex for degrading enzymes,  
such as nucleases, is a factor relevant for the effectivity.

Oligonucleotides are oligomers in which the  
monomers are nucleotides. Nucleotides are phosphate esters  
of nucleosides, which are built of a purine or pyrimidine  
25 base and a sugar. The backbone of each nucleotide consists  
of alternating sugars and phosphate groups.

The stability and binding affinity of the  
nucleotides may for example be influenced by modification of  
the base. Research in that direction (1-5) showed that such  
30 modifications only lead to less stable duplexes. Alterations  
in the backbone or the incorporation of new structures  
therein did lead to an increased nuclease stability but had  
only an adverse effect on their binding affinity for  
complementary strands. Modification of the sugars led to a  
35 merely limited increase in the affinity for the target  
molecule (6-8).


It is the object of the present invention to provide new oligomers, which have an improved stability and binding affinity as compared to the known oligomers.

It has now been found that oligomers, consisting completely or partially of 1,5-anhydro-2,3-dideoxy-D-arabino-hexitol nucleoside analogues, wherein the hexitol is coupled via its 2-position to the heterocyclic ring of a pyrimidine or purine base, are capable of binding to naturally occurring oligonucleotides. The monomers of which the oligomers are at least partially composed are presented by the formula I:



(I)


wherein B is a heterocyclic ring which is derived from pyrimidine or purine base. The monomers are connected to each other through a phosphordiester bridge with formula II representing the structure of these oligomers,



(II)

wherein B is a heterocyclic ring which is derived from a pyrimidine or purine base and, wherein l is an integer from 0 to 15, k and m each are integers from 1 to 15, but if  $k > 1$ , then m may be 0 and if  $m > 1$ , k may be 0; and, wherein X represents oxygen or sulfur. All possible salts of the compound of formula II are included in the invention. The monomers of formula I are the subject of European patent application No. 92201803.1. The oligomers of formula II are novel compounds. They display a certain similarity with oligonucleotides consisting of the naturally occurring 2'-deoxynucleosides, but the sugars of the monomers are enlarged because a methylene group is incorporated in between the ring oxide and the carbon, which is coupled to the base.

According to the invention it has been found that the oligomers of formula II and their salts exhibit sequence specific binding to natural oligonucleotides represented by formula III




wherein k is an integer and wherein B has the same designation as in formula's I and II. A new class of hybridons or sequence-specific binding polymers has therefore been found.

The fact that oligomers according to the invention, consisting at least partially of pyranose nucleosides, have a high binding affinity is very surprising. The study of oligonucleotides built up from monomeric pyranose nucleotides has been undertaken over the past years inter alia by the group of A. Eschenmoser et al.. Eschenmoser investigated nature's selection of furanoses as sugar building blocks for nucleic acids (9). However, he did

not indicate the requirements which a suitable antisense molecule should meet to accomplish a good binding to naturally occurring furanose-DNA.

The present inventors however investigated which pyranose-like oligonucleotide would be able to form stable duplexes with natural furanose-DNA (10, 11). Theoretically, a pyranose oligonucleotide has a free energy advantage over a furanose oligomer because of less entropy changes during duplex formation.

However, the pyranose-like oligonucleotides studied by the present inventors before were not able or not sufficiently able to bind to complementary strands of natural furanose-DNA. These pyranose-like oligonucleotides consisted of 2,3-dideoxy- $\beta$ -D-erythro-hexopyranosyl nucleosides (formula V), 2,4-dideoxy- $\beta$ -D-erythro-hexopyranosyl nucleosides (formula VI) and/or 3,4-dideoxy- $\beta$ -D-erythro-hexopyranosyl nucleosides (formula VII), respectively.



25 The fact that sequence-specific binding is found for the oligomers of formula II, comprising pyranoses as sugar building blocks is therefore even more surprising. Enlarging the furan ring of furanose compounds to a pyran ring did not yield oligomers capable of binding natural oligonucleotides. Thus, the effect of enlarging the pento-  
30 furanosyl ring to a 1,5-anhydrohexitol ring could not be anticipated.

The compounds according to the invention are therefore oligomers of nucleoside analogues wherein a  
35 1,5-anhydro-2,3-dideoxy-D-hexitol is coupled via its 2-position according to an arabino-configuration to the heterocyclic ring of a pyrimidine or purine base.

The oligomers consist of the above nucleoside analogues connected to each other as phosphate diesters or thiophosphate diesters. The oligomers can be represented by the formula II wherein k, l, m, B and X have the above stated designations. The oligomers can be exclusively composed of the hexitol nucleoside analogues of the formula I (with l in formula II equalling zero) or can have natural 2'-deoxynucleosides interspersed or at the end of the molecule (with l in formula II equalling one or greater).


10 The hexitol has the (D)-configuration and the stereochemistry of the substituents is according to an arabino configuration.

When group B is derived from a pyrimidine base it can be either cytosine, 5-methyl cytosine, uracil or thymine. When B is derived from a purine base it can be an adenine, guanine, 2,6-diaminopurine, hypoxanthine or xanthine ring, or a deaza derivative of one to these.

The nucleoside analogues, monomer components of the present invention, can be prepared in different ways and one of the preparation methods is subject of the European patent application no. 92.201803.1. These syntheses haven been described likewise in Verheggen et al. (12). Assembly of the monomers into an oligomer follows the classical schemes and can be done either by standard phosphoramidite chemistry (compare ref. 13) or by H-phosphate chemistry (compare ref. 14). All procedures are conveniently carried out on an automated DNA synthesizer as for standard oligonucleotide synthesis. For these standard conditions reference is made to Methods in Molecular Biology (15).

30 The preferred method is the phosphoramidite method making use of the phosphoramidites of the hexitol nucleoside analogues as the incoming building blocks for assembly in the "6'-direction". The phosphoramidites are represented by formula VIII wherein B\* is a protected base moiety suitable for oligonucleotide synthesis (e.g. thymine, N<sup>4</sup>-benzoyl-cytosine, N<sup>6</sup>-benzoyladenine en N<sup>2</sup>-isobutyrylguanine, represented by the formula's IX, X, XI and XII, respectively).

6



The products of formula VIII can be prepared according to standard procedures. Protection of the base moieties of cytosine, adenine or guanine is accomplished following a transient protection strategy for the hydroxyl moieties of the compounds of formula I (16). Preferably, however, the base protection is carried out by acylation of the 4,6-benzylidene protected nucleoside analogues 1a-d, which are intermediates in the synthesis of the monomers of the above stated formula I.


Following acylation of the exocyclic amino functionality, the benzylidene moiety is removed with 80% acetic acid to obtain 3a-d. To obtain compound 3c the p-nitro-phenylethyl group can be removed with DBU.

The primary hydroxyl function of the 1,5-anhydro-hexitol analogues 3a-d can be protected with a dimethoxy-trityl group to yield 4a-d. Conversion to the phosphoramidite building blocks 5a-d suitable for incorporation into an oligonucleotide chain can be accomplished with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite. Supports containing a 1,5-anhydrohexitol analogue can be prepared by succinylation of the compounds 4a-d yielding 6a-d, which can be coupled to the amino function of either long chain



alkylamino controlled pore glass (CCAA-CPG) or a suitable amino functionalized polystyrene (e.g. Tentagel®-RAPP Polymere) making use of a carbodiimide, and yielding 7a-d (for functionalization of supports viz. ref. 17)

5           After assembly, the obtained oligonucleotides are cleaved from the support and deprotected by ammonia treatment for 16 hours at 55°C. Purification of the obtained oligomers of the above stated formula II can be accomplished in several ways (18). The preferred method is purification  
10 by anion-exchange FPLC at a basic pH of 12 to disrupt all possible secondary structures (10). Desalting can be performed by simple gel filtration techniques followed by lyophilization. All acceptable salts can be prepared in conventional manner.



(i) 80% HOAc; (ii) dimethoxytrityl chloride, pyridine; (iii) *N,N*-diisopropylethylamine, 2-cyano-*N,N*-diisopropylchlorophosphoramidite, CH<sub>2</sub>Cl<sub>2</sub>; (iv) DMAP, succinic anhydride, pyridine; (v) pre-activated LCAA-CPG, DMAP, Et<sub>3</sub>N, 1-(3-diethylaminopropyl)-3-ethylcarbodiimide.HCl, pyridine.

As stated above, the oligomers display sequence-specific binding to natural oligonucleotides. They show stronger binding to a complementary natural oligodeoxynucleotide than the unmodified sequence and they are endowed with much higher biochemical stability. In this manner they can advantageously be used for antisense strategies which comprise diagnosis, hybridization, isolation of nucleic acids, site-specific DNA modification and therapeutics and all anti-sense strategies currently being pursued with natural oligodeoxynucleotides.

### EXAMPLES

The compounds according to the invention as well as their chemical synthesis and the preparation of starting materials are further illustrated in the following examples, which are not however intended to limit the invention.

The following abbreviations are being used:

FABMS = fast atom bombardment mass spectrometry

Thgly = thioglycerol

NBA = nitrobenzylalcohol

Synthesis of the 1,5-anhydro-2,3-dideoxy-2-substituted-D-arabino-hexitol nucleoside analogues and of their 4,6-O-benzylidene protected derivatives has been described by Verheggen et al. (12).

### EXAMPLE 1

#### Base-protected nucleoside analogues

1.1. 1,5-anhydro-2-(N<sup>6</sup>-benzoyladenin-9-yl)-2,3-dideoxy-D-arabinohexitol (3b)

To a solution of 2.3 g (6.51 mmol) 1,5-anhydro-4,6-O-benzylidene-2-(adenin-9-yl)-2,3-dideoxy-D-arabino-hexitol in 20 ml of dry pyridine, 0.9 ml (7.8 mmol) of benzoylchloride was added at 0°C. After stirring for 4 hours at room temperature, the mixture was cooled on an ice bath and 2 ml of H<sub>2</sub>O was added. After addition of 1.5 ml of a concentrated NH<sub>3</sub> solution (33% g/v) and further stirring for 45 min. at room temperature, the mixture was evaporated. The

residue was purified by column chromatography ( $\text{CH}_2\text{Cl}_2$ -MeOH, 98:2) yielding 1.92 g (4.19 mmol, 64% yield) of 1,5-anhydro-4,6-O-benzylidene-2-(N<sup>6</sup>-benzoyladenine-9-yl)-2,3-dideoxy-D-arabinohexitol.

5 This was further treated with 100 ml of 80% acetic acid at 60°C for 5 hours to remove the benzylidene moiety. Evaporation, coevaporation with toluene and purification by column chromatography ( $\text{CH}_2\text{Cl}_2$ -MeOH, 95:5 to 90:10) yielded 1.10 g (2.98 mmol, 71% yield) of the compound mentioned in  
10 the title of this example.

UV(MeOH)  $\lambda_{\text{max}}$  282 nm ( $\epsilon=20200$ )

FABMS (Thgly, NaOAc) m/e: 392 (M+Na)<sup>+</sup>. 240 (B+2H)<sup>+</sup>

<sup>1</sup>H NMR (DMSO- $d_6$ )  $\delta$  1.94 (m, 1H, H-3'ax), 2.32 (m, 1H, H-3'eq),  
3.21 (m, 1H, H-5'), 3.42-3.76 (m, 3H, H-4', H-6', H-6''),  
15 3.90 (dd, <sup>2</sup>J=13 Hz, 1H, H-1'ax), 4.27 (dd, <sup>2</sup>J=12.2 Hz, 1H, H-1'eq), 4.67 (t, J=5.7 Hz, 1H, 6'-OH), 4.88-5.00 (m, 2H, H-2', 4'-OH), 7.47-7.68 (m, 3H, aromatic H), 8.00-8.07 (m, 2H aromatic H) 8.60 (s, 1H), 8.73 (s, 1H) (H-2, H-8) ppm.

<sup>13</sup>C NMR (DMSO- $d_6$ )  $\delta$  35.8 (C-3'), 50.7 (C-2'), 60.5, 60.7 (C-4', C-6'), 67.9 (C-1'), 83.1 (C-5'), 125.1 (C-5), 128.5 (Co, Cm), 132.5 (Cp), 133.6 (Cx), 143.5 (C-8), 150.3 (C-4), 151.4 (C-2), 152.4 (C-6) ppm.

1.2. 1,5-Anhydro-2,3-dideoxy-2-(N<sup>2</sup>-isobutyrylguanin-9-yl)-D-arabinohexitol (3c)  
25

Alkylation of N<sup>2</sup>-isobutyryl-O<sup>6</sup>-[2-(p-nitrophenyl)ethyl]guanine (1.85 g, 7.5 mmol) with 1,5-anhydro-4,6-O-benzylidene 3-deoxy-D-glucitol (1.18 g, 5 mmol) yielded 1.35 g of crude 1,5-anhydro-4,6-O-benzylidene-2,3-dideoxy-2-(N<sup>2</sup>-isobutyryl-guanin-9-yl)-D-arabinohexitol after removal of  
30 the p-nitrophenyl-ethyl group with 1.5 ml (10 mmol) of DBU in anhydrous pyridine for 16 hours and purification by flash column chromatography ( $\text{CH}_2\text{Cl}_2$ -MeOH, 99:1 to 97:3).

Hydrolysis of the benzylidene moiety with 100 ml of 80% HOAc  
35 (5 hours at 60°C) gave the desired compound 3c (610 mg, 1.74 mmol, 34% overall yield) after column chromatography ( $\text{CH}_2\text{Cl}_2$ -MeOH, 90:10).

UV(MeOH)  $\lambda_{\text{max}}$  273 nm

FABMS (Thgly, NaOAc) m/e:352(M+H)<sup>+</sup>

<sup>1</sup>H NMR δ 1.11 (d, J = 6.7 Hz, 6H, CH<sub>3</sub>), 1.93 (m, 1H, H-3'ax), 2.11-2.38 (m, 1H, H-3'eq), 2.80 (q, 1H, CHMe-2), 3.25 (m, 1H, H-5'), 3.42-3.78 (m, 3H, H-4', H-6', H-6''), 3.89 (dd, <sup>2</sup>J=13Hz, 1H, H-1'), 4.21 (dd, <sup>2</sup>J=13Hz, 1H, H-1''), 4.69 (dd, <sup>2</sup>J=13Hz, 1H, H-1'), 4.21 (dd, <sup>2</sup>J=13Hz, 1H, H-1''), 4.69 (dd, <sup>2</sup>J=13Hz, 1H, H-1'), 4.21 (dd, <sup>2</sup>J=13Hz, 1H, H-1''), 4.69 (dd, <sup>2</sup>J=13Hz, 1H, H-1').

<sup>13</sup>C NMR δ 19.4 (CH<sub>3</sub>), 34.5 (CHMe<sub>2</sub>), 35.8, (C-3'), 50.5 (C-2'), 60.5, 60.7 (C-4', C-6'), 67.9 (C-1'), 83.1 (C-5'), 116.7 (C-5), 141.7 (C-8), 152.0 (C-4), 153.0 (C-2), 159.8 (C-6), 175.2 (C=O) ppm.

10

## EXAMPLE 2

### Dimethoxytritylation van de nucleoside analogues

2.1. 1,5-Anhydro-6-O-dimethoxytrityl-2-(thymin-1-yl)-2,3-dideoxy-D-arabinohexitol (4a)

1,5-Anhydro-2-(thymin-2-yl)-2,3-dideoxy-D-arabinohexitol (3a) (330 mg, 1.29 mmol) was dissolved in 20 ml of anhydrous pyridine, and 480 mg (1.42 mmol) of dimethoxytrityl chloride was added. The mixture was stirred overnight at room temperature, diluted with 100 ml of CH<sub>2</sub>Cl<sub>2</sub> and washed twice with 100 ml of saturated NaHCO<sub>3</sub> solution. The organic layer was dried, evaporated and coevaporated with toluene. The resulting residue was purified by column chromatography (with a gradient of 0 to 3% MeOH in CHCl<sub>3</sub> containing 1% triethylamine) to yield 373 mg (0.67 mmol, 52%) of the title compound as a foam.

FABMS (Thgly, NaOAc) m/e:581(M+Na)<sup>+</sup>.127 (B+2H)<sup>+</sup>

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.60-2.50 (m, 2H, H-3', H-3''), 1.91 (s, 3H, CH<sub>3</sub>), 3.12-3.62 (m, 2H, H-5', H-4'), 3.77 (s, 6H, 2x OCH<sub>3</sub>), 3.65-4.17 (m, 4H, H-6', H-6'', H-1', H-1''), 4.53 (s, 1H, H-2'), 4.88 (d, 1H, J=5.1, Hz 4'-OH), 6.81 (d, J=8.7, 4H, aromatic H), 7.09-7.53 (m, 9H, aromatic H), 8.09 (s, 1H, H-6), 9.10 (br s, 1H, NH) ppm

<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 12.5 (CH<sub>3</sub>), 35.5 (C-3'), 50.7 (C-2'), 54.9 (OCH<sub>3</sub>), 62.4, 63.1 (C-4', C-6'), 68.2 (C-1'), 81.1 (C-5'), 86.0 (Ph<sub>3</sub>C) 110.0 (C-5), 138.4 (C-6), 151.0 (C-2), 163.8 (C-4), 112.9, 126.6, 127.5, 127.8, 129.7, 135.6, 144.6, 158.3 (aromatic C) ppm.

2.2. 1,5-Anhydro-6-O-dimethoxytrityl-2-(N<sup>6</sup>-benzoyladenine-9-yl)-2,3-dideoxy-D-arabinohexitol (4b)

A solution of 370 mg (1 mmol) of the nucleoside 3b and 400 mg (1.2 mmol) of dimethoxytritylchloride in 25 ml of pyridine dry was stirred at room temperature for 16 hours. The mixture was diluted with 100 ml of CH<sub>2</sub>Cl<sub>2</sub> and washed twice with 100 ml of saturated NaHCO<sub>3</sub> solution. The organic layer was dried, evaporated and coevaporated with toluene. The residue was purified by column chromatography (0 to 3% of MeOH in CH<sub>2</sub>Cl<sub>2</sub> with 0.2% pyridine) to obtain 400 mg (0.6 mmol, 63% yield) of compound 4b as a foam. FABMS (Thgly, NaOAc) m/c: 694 (m+Na)<sup>+</sup>, 240 (B+2H)<sup>+</sup>.

2.3. 1,5-Anhydro-6-O-dimethoxytrityl-2-(N<sup>2</sup>-isobutyrylguanin-9-yl)-2,3-dideoxy-D-arabinohexitol (4c)

A solution of 580 mg (1.65 mmol) of the nucleoside 3c and 670 mg (2.0 mmol) of dimethoxytritylchloride in 25 ml of dry pyridine was stirred at room temperature for 16 hours. The mixture was diluted with 100 ml of CH<sub>2</sub>Cl<sub>2</sub> and washed twice with 100 ml of saturated NaHCO<sub>3</sub> solution. The organic layer was dried, evaporated and coevaporated with toluene. The residue was purified by column chromatography with a gradient of 0 to 3% MeOH in CH<sub>2</sub>Cl<sub>2</sub> containing 0.2% pyridine to obtain 770 mg (1.18 mmol, 71% yield) of compound 4c as a foam. FABMS (NBA) m/e: 654 (M+H)<sup>+</sup>.

2.4. Preparation of the amidite building blocks (5a-c)

A mixture of the 6'-O-protected nucleoside (0.5 mmol), 3 equivalents of dry N,N-diisopropyl-ethylamine and 1.5 equivalents of 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite in 2.5 ml of dry CH<sub>2</sub>Cl<sub>2</sub> was stirred at room temperature for 3 hours. After addition of 0.5 ml of EtOH and further stirring for 25 min, the mixture was washed with 5% NaHCO<sub>3</sub>-solution (15 ml) and saturated NaCl solution, dried and evaporated. Flash column chromatography with Et<sub>3</sub>N afforded the amidite as a white foam which was dissolved in a small amount of dry CH<sub>2</sub>Cl<sub>2</sub> and added dropwise to 100 ml of

cold (-50°C) n-hexane. The precipitate was isolated, washed with n-hexane, dried and used as such for DNA synthesis.

The following table gives the eluting solvent and yield after precipitation for the different amidites:

| compound | solvent                                  | solvent<br>ratio | yield | FABMS(NBA<br>) m/e     |
|----------|--|------------------|-------|------------------------|
| 5a       | n-hexane/ethyl acetate/<br>triethylamine | 23:75:2          | 62%   | 759 (M+H) <sup>+</sup> |
| 5b       | n-hexane/ethyl acetate/<br>triethylamine | 50:48:2          | 65%   | 872 (M+H) <sup>+</sup> |
| 5c       | n-hexane/acetone/<br>triethylamine       | 55:43:2          | 56%   | 854 (M+H) <sup>+</sup> |

**EXAMPLE 3****Succinylation of the 6-O-protected nucleoside analogues**

10 3.1. 1,5-Anhydro-6-O-dimethoxytrityl-4-O-succinyl-2-(thymine-1-yl)-2,3-dideoxy-D-arabinohexitol (6a)

A mixture of 80 mg (0.14 mmol) 4a, 9 mg (0.07 mmol) of DMAP and 43 mg (0.14 mmol) of succinic anhydride in 5 ml of anhydrous pyridine was stirred at room temperature  
 15 for 24 hours. As the reaction was incomplete an additional amount of 43 mg (0.43 mmol) was added and the mixture was stirred for another 24 hours. The solution was evaporated and coevaporated with toluene. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, the organic layer washed with saturated NaCl  
 20 solution and water, dried and evaporated to give 78 mg (0.12 mmol, 86% yield) of 6a as a white foam.

3.2. 1,5-Anhydro-6-O-dimethoxytrityl-4-O-succinyl-2-(N<sup>6</sup>-benzoyladenine-9-yl)-2,3-dideoxy-D-arabinohexitol (6b)

25 The same procedure as described for 6a was used for the synthesis of 6b. An amount of 260 mg (0.39 mmol) of 4b yielded 256 mg (0.33 mmol, 85% yield) of the captioned compound as a foam.

30 **EXAMPLE 4**

**Production of oligonucleotides****4.1. Preparation of solid support**



A mixture of 80  $\mu\text{mol}$  of the succinates (6a, b), 400 mg of pre-activated LCAA-CPG (17), 5 mg (40  $\mu\text{mol}$ ) of DMAP, 35  $\mu\text{l}$  of  $\text{Et}_3\text{N}$  and 153 mg of (800  $\mu\text{mol}$ ) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.HCl in 4 ml of anhydrous pyridine was first sonicated for 5 min and then shaken at room temperature for 16 hours. After shaking, the CPG solid support was filtered off and washed successively with pyridine, methanol and  $\text{CH}_2\text{Cl}_2$  followed by drying under vacuum. The unreacted sites on the surface of the support were capped using 1.5 ml of 1-methylimidazole in THF (Applied Biosystems) and 1.5 ml of acetic anhydride-lutidine-THF 1:1:8 (Applied Biosystems). After shaking for 4 hours at room temperature, the solid support was filtered off, washed with  $\text{CH}_2\text{Cl}_2$  and dried under vacuum. Colorimetric dimethoxytrityl analysis indicated a loading of 18.5  $\mu\text{mol/g}$  for 7a and 21.5  $\mu\text{mol/g}$  for 7b.

#### 4.2. DNA-synthesis

Oligonucleotide synthesis was performed on an ABI 381A DNA synthesizer (Applied Biosystems) using the phosphoramidite method (end dimethoxytrityl off). The obtained sequences were deprotected and cleaved from the solid support by treatment with concentrated ammonia (55°C, 16 hours). After purification on a NAP-10<sup>®</sup> column (Sephadex G25-DNA grade, Pharmacia), eluted with buffer A (see below), purification was done on a mono-Q<sup>®</sup> HR 10/10 anion exchange column (Pharmacia) with the following gradient system [A= 10 mM NaOH, pH 12.0, 0.1 M NaCl; B= 10 mM NaOH, pH 12.0, 0.9 M NaCl; gradient used depended on the oligo; flow rate 2 ml/min]. The low pressure liquid chromatography system consisted of a Merck-Hitachi L6200 A Intelligent Pump, a Mono Q<sup>®</sup> HR 10/10 column (Pharmacia), an Uvicord SJI 2138 UV detector (Pharmacia-LKB) and a recorder. The product containing fraction was desalted on a NAP-10<sup>®</sup> column and lyophilized.

#### EXAMPLE 5

##### Melting temperatures

Oligomers were dissolved in the following buffer:  
0.1 M NaCl, 0.02 M potassium phosphate pH=7.5, 0.1 mM EDTA.  
The concentration was determined by measuring the absorbance  
at 260 nm at 80°C and assuming the 1,5-anhydrohexitol  
5 nucleoside analogues to have the same extinction coefficients  
in the denatured state as the natural nucleosides.  
For the adenine monomers  $\epsilon = 15000$   
For the thymine monomers  $\epsilon = 8500$   
For the guanine monomers  $\epsilon = 12500$   
10 For the cytosine monomers  $\epsilon = 7500$

The concentration in all experiments was approximately 4  $\mu$ M  
of each strand. Melting curves were determined with a Uvikon  
940 Spectrophotometer. Cuvettes were thermostated with water  
circulating through the cuvette holder and the temperature  
15 of the solution was measured with a thermistor directly  
immersed in the cuvette. Temperature control and data  
acquisition were done automatically with an IBM/PC AT  
compatible computer. The samples were heated and cooled at a  
rate of 0.2°C/min and no difference could be observed  
20 between heating and cooling melting curves. Melting curves  
were evaluated by taking the first derivative of the  
absorbance versus temperature curve. Examples of the  
synthesized oligonucleotides together with their melting  
points are given in table 1 through 4.

25

#### Table 1

Melting points of oligonucleotides with a single  
anhydrohexitol nucleoside (A\*, T\*) incorporated (measured at  
0.1 M NaCl-concentration) in the middle of an A<sub>13</sub>/T<sub>13</sub> duplex.

| $d(T)_6Xd(T)_6$<br>$d(A)_6Yd(A)_6$ |      |      |      |      |
|------------------------------------|------|------|------|------|
| Y\X                                | G    | C    | A    | T    |
| A                                  | 20.0 | 17.9 | 18.5 | 34.0 |
| A*                                 | 20.2 | 17.1 | 17.7 | 32.1 |
| X\Y                                | G    | C    | T    | A    |
| T                                  | 21.0 | 20.7 | 21.3 | 34.0 |
| T*                                 | 15.1 | 15.2 | 18.3 | 28.7 |

10

From Table 1 it is clear that incorporation of 1,5-anhydro-2-(adenine-9-yl)-2,3-dideoxy-D-arabinoheptitol into an oligodeoxyadenylate gives nearly identical helix-coil transitions as insertion of a natural 2'-deoxyadenosine. It should be mentioned, however, that one mismatch in a oligodeoxyadenylate/oligothymidine duplex has a large effect on duplex stability. On the contrary, substitution of thymidine by 1,5-anhydro-2,3-dideoxy-2-(thymine-1-yl)-D-arabinoheptitol into an oligothymidylate gives a substantial decrease in melting temperature. In contrast to previous observations of our laboratory with 2,4-dideoxy- $\beta$ -D-erythro-hexopyranosyl nucleosides where an A\*.G [A\*:9-2,4-dideoxy- $\beta$ -D-erythrohexopyranosyl)adenine] mismatch gives more stable hybridization than an A\*.T [A\*:9-2,4-dideoxy- $\beta$ -D-erythrohexopyranosyl)adenine] base pairing (11) there is no alteration in base pairing specificity with the 1,5-anhydroheptitol nucleosides when using oligodeoxyadenylate/oligothymidine duplex as model.

30 Table 2

Melting temperature of completely modified oligonucleotides and of oligonucleotides modified at both ends, determined at 0.1 M NaCl.

|  | T <sub>m</sub> (°C) | Hypochrommicity |
|--|---------------------|-----------------|
| equimol.mixt.with(dA) <sub>13</sub> (14)                   |                     |                 |
| (dT) <sub>6</sub> T*(dT) <sub>6</sub> (8)                  | 27.8                | 33%             |
| (T*) <sub>2</sub> (dT) <sub>9</sub> (T*) <sub>2</sub> (9)  | 27.6                | 32%             |
| (T*) <sub>13</sub> (10)                                    | 45.4(1)             | 49%             |
| equimol.mixt.with(dT) <sub>13</sub> (15)                   |                     |                 |
| (dA) <sub>6</sub> A*(dA) <sub>6</sub> (4)                  | 31.8                | 31%             |
| (A*) <sub>2</sub> (dA) <sub>9</sub> (A*) <sub>2</sub> (12) | 30.3                | 33%             |
| (A*) <sub>13</sub> (13)                                    | 21.0                | 49%             |
| (T*) <sub>13</sub> :(A*) <sub>13</sub> (10:13)             | 76.3                | ND              |
| (dT) <sub>13</sub> :(dA) <sub>13</sub> (15:14)             | 34.0                | 35%             |

(1) measured at 284 nm

Single stranded oligoA\* and oligoT\* both show an ordered  
 15 structure but, in contrast to the results at high salt  
 concentration, (results not shown) polyT\* does not show the  
 same tendency for homoduplex formation. This is demonstrated  
 by the more or less linear increase of the UV absorption  
 with temperature, both for oligoA\* and oligoT\*. An equimolar  
 20 mixture of oligoT\* and oligodeoxyadenylate shows a melting  
 temperature of 45°C with a hypochromicity of 49% when  
 measured at 284 nm. It is known that, by changing salt  
 concentration, structural transition occurs in DNA and this  
 is here clearly the case. The oligoT\*: oligodeoxyadenylate  
 25 association is favored at lower salt concentration while the  
 formation of oligoT\* homoduplexes is favored at high salt  
 concentrations. The thermal behavior of the complex at 260  
 nm, however, indicates that the oligoT\*:oligodeoxy-adenylate  
 association is not a classical helix-coil transition. At 260  
 30 nm, the hypochromicity first decreases, showing a minimum at  
 46°C (the melting point observed at 484 nm) and then  
 increases. Fully modified mixed sequences (two hexamers and  
 a dodecamer) containing the adenine (A\*) and guanine (G\*)  
 nucleoside analogues have been evaluated likewise.

Table 3

Melting temperatures of fully modified hexamers

| Sequence (equimol.mixt.with complement) |                 | T <sub>m</sub> (°C) |
|---|-----------------|---------------------|
| (16)                                    | 6'-A*G*G*A*G*A* | 31.2                |
| (17)                                    | 5'-AGGAGA       | 10.0                |
| (18)                                    | 6'-G*A*G*A*G*A* | 14.7                |
| (19)                                    | 5'-GAGAGA       | 9.5                 |

determined at 1M NaCl, 20 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.5, EDTA 0.1 mM

- 10 Duplexes were formed with the complementary sequences  
 5'-TCTCCT(20) for 16 and 17, and  
 5'-TCTCTC(21) for 18 and 19 respectively.

Although for some of these sequences melting points could be  
 15 determined for the hexamers, thermal denaturation of these  
 oligonucleotides was studied in 1 M NaCl (containing 20 mM  
 K<sub>2</sub>HPO<sub>4</sub>, pH 7.5 and 0.1 mM EDTA). The most important  
 phenomenon is the clear formation of a duplex between the  
 pyranose-like oligonucleotides and their natural counter-  
 20 parts. Moreover, these modified duplexes are more stable  
 than the control duplexes consisting of exclusively Watson-  
 Crick base pairs.

Striking however is the large difference in  
 melting temperature for sequences 16 (T<sub>m</sub> = 31.2°C) and 17  
 25 (T<sub>m</sub> = 14.7°C) with their antiparallel complementary  
 oligonucleotides. Where both modified oligo's contain 3 G\*'s  
 and 3 A\*'s differing only in their sequence order, the  
 melting temperature for 16 doubles the one for 18. This  
 sequence dependent effect is only marginally reflected by  
 30 the control oligonucleotides 17 and 19.

Table 4

Melting temperatures of fully modified dodecamers  
 containing A\* and G\*

| Sequence (equimol.mixt.with complement) |                                | Tm with 24(°C) |
|---|--------------------------------|----------------|
| (22)                                    | 6'-A*G*G* G*A*G* A*G*G* A*G*A* | 64.8           |
| (23)                                    | 5'-AGG GAG AGG AGA             | 49.0           |

determined at 0.1 M NaCl

5 (24) 5'-TCT CCT CTC CCT


Looking at the dodecamers one notices again an increased stability of the fully modified oligonucleotide compared to its control sequence 23 with an increase in melting temperature of 16°C, when evaluating both sequences with their complementary antiparallel sequence 24.

## REFERENCES

1. Beaucage, S.L. & Iyer, R.P., Tetrahedron 49, 6123-6194 (1993)
2. Sanghvi et al., Nucleosides and Nucleotides 10, 345-346 (1991)
3. Chollet et al., Chemica Scripta 26, 37-40 (1986)
4. Seela, F. & Kehne, A., Biochemistry 24, 7556-7561 (1985)
5. Wagner et al., Science 260, 1510-1513 (1993)
6. Inoue et al., Nucleic Acids Res. 15, 6131-6148 (1987)
7. Perbost et al., Biochem. Biophys. Res. Commun. 165, 742-747 (1989)
8. Gagnor et al., Nucleic Acids Res. 15, 10419-10436 (1987)
9. Eschenmoser, A., Pure & Appl. Chem. 65, 1179-1188 (1993)
10. Augustyns et al., Nucleic Acid Res. 20, 4711-4716, (1992)
11. Augustyns et al., Nucleic acids Res. 21, 4670-4676 (1993)
12. Verheggen et al., J. Med. Chem. 36, 2033-2040 (1993)
13. Matteucci en Caruthers, J. Am. Chem. Soc. 103, 3185-3191 (1981)
14. Froehler et al., Nucl. Acids Res. 14, 5399-5407 (1986)
15. Methods in Molecular Biology, vol. 20, Protocols for oligonucleotides and analogs, S. Agrawal ed., Humana Press, Totowa, New Jersey, U.S.A.
16. Ti et al., J. Am. Chem. Soc. 104, 1316-1319 (1982)
17. Pon et al., Biotechniques 6, 768-775 (1988)
18. Methods in Molecular Biology vol. 26, hoofdstuk 9 "Analysis and Purification of synthetic oligonucleotides by HPLC"; S. Agrawal ed., Humana Press, Totowa, New Jersey, USA

## CLAIMS

1. Oligomers consisting completely or partially of 1,5-anhydrohexitol nucleoside analogues represented by the general formula I




(I)

10

wherein B is a heterocyclic ring which is derived from a pyrimidine or purine base.

2. Oligomers as claimed in claim 1, characterized by the general formula II

15



(II)

25

30

wherein B is a heterocyclic ring which is derived from a pyrimidine or purine base, and

wherein k, l, and m each are integers from 0 to 15, provided

35 k and m are at least one; but if k > 1, then m may be 0; and

if m > 1, k may be 0; and,

wherein X represents oxygen or sulfur, and salts thereof.



3. Oligomers as claimed in claim 1 or 2,  
characterized in that the heterocyclic ring is selected from  
the group consisting of cytosine, 5-methylcytosine, uracil  
and thymine, or deaza derivatives thereof.

5 4. Oligomers as claimed in claim 1 or 2,  
characterized in that the heterocyclic ring is selected from  
the group consisting of adenine, guanine, 2,6-diaminopurine,  
hypoxanthine and xanthine, or deaza derivatives thereof.


5. Oligomers as claimed in any one of the  
10 preceding claims, wherein the compound of formula I has the  
(D)-configuration and the substituents are located in the  
arabino-configuration.

6. Oligomers as claimed in any one of the claims  
1-5 for use in antisense techniques.

15 7. Oligomers for the use as claimed in claim 6,  
characterized in that the antisense techniques comprise  
diagnosis, hybridization, isolation of nucleic acids, site-  
directed DNA modification and therapy.

8. Method of preparing oligomers of formula II,  
20 comprising coupling a suitable amount of monomers of formula  
I.

9. Phosphoramidites of the general formula VIII



30

wherein B<sup>+</sup> is a protected base, for use in the preparation  
of oligomers of claim 1.

International Application No

PCT/EP 95/03248

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07H21/00 C07F9/6561 C07F9/6558 A61K31/70 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07H C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                 | Relevant to claim No. |
|------------|--|-----------------------|
| Y          | WO,A,93 25565 (STICHTING REGA) 23 December 1993<br>cited in the application<br>see claims<br>---   | 1-9                   |
| Y          | US,A,5 314 893 (BRISTOL-MYERS SQUIBB CO.)<br>24 May 1994<br>see column 1 - column 3<br>---<br>-/-- | 1-9                   |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&\* document member of the same patent family

Date of the actual completion of the international search

19 December 1995

Date of mailing of the international search report

29. 12. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Day, G

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| Y          | <p>NUCLEIC ACIDS RESEARCH,<br/>vol. 20, no. 18, 1992 OXFORD GB,<br/>pages 4711-4716,<br/>AUGUSTYNS K. ET AL. 'INCORPORATION OF<br/>HEXOSE NUCLEOSIDE ANALOGUES INTO<br/>OLIGONUCLEOTIDES: SYNTHESIS AND<br/>BASE-PAIRING PROPERTIES AND ENZYMATIC<br/>STABILITY'<br/>cited in the application<br/>see the whole document<br/>---</p>                                      | 1-9                   |
| Y          | <p>NUCLEIC ACIDS RESEARCH,<br/>vol. 21, no. 20, 1993 OXFORD GB,<br/>pages 4670-4676,<br/>AUGUSTYNS K. ET AL. 'HYBRIDIZATION<br/>SPECIFICITY, ENZYMATIC ACTIVITY AND<br/>BIOLOGICAL (HA-RAS) ACTIVITY OF<br/>OLIGONUCLEOTIDES CONTAINING<br/>2,4-DIDEOXY-BETA-D-ERYTHRO-HEXOPYRANOSYL<br/>NUCLEOSIDES'<br/>cited in the application<br/>see the whole document<br/>---</p> | 1-9                   |
| P,X        | <p>ANGEWANDTE CHEMIE INTERNATIONAL EDITION.,<br/>vol. 34, no. 12, 7 July 1995 WEINHEIM DE,<br/>pages 1338-1339,<br/>VAN AERSCHOT A. '1,5-ANHYDROHEXITOL<br/>NUCLEIC ACIDS, A NEW PROMISING ANTISENSE<br/>CONSTRUCT'<br/>see the whole document<br/>-----</p>  | 1-9                   |

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/03248

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO-A-9325565                              | 23-12-93            | AU-B- 4301393              | 04-01-94            |
|   |                     | EP-A- 0646125              | 05-04-95            |
|   |                     | NL-A- 9300058              | 17-01-94            |
| -----                                     |                     |                            |                     |
| US-A-5314893                              | 24-05-94            | AU-B- 5394694              | 28-07-94            |
|   |                     | CA-A- 2111549              | 26-07-94            |
|   |                     | EP-A- 0608809              | 03-08-94            |
|   |                     | JP-A- 6271574              | 27-09-94            |
|   |                     | US-A- 5414096              | 09-05-95            |
|   |                     | US-A- 5414000              | 09-05-95            |
| -----                                     |                     |                            |                     |